Breaking Finance News

Esperion Therapeutics Inc (NASDAQ:ESPR) price target upped to $16.00, released a research note today by Zacks Investment Research

In a report released on 10/5/2016 Zacks Investment Research increased the stock price target of Esperion Therapeutics Inc (NASDAQ:ESPR) to $16.00 reporting a potential upside of 0.13%.

Having a price of $14.13, Esperion Therapeutics Inc (NASDAQ:ESPR) traded 3.59% higher on the day. With the last stock price up 0.42% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. ESPR has recorded a 50-day average of $11.92 and a two hundred day average of $14.07. Trade Volume was down over the average, with 343,891 shares of ESPR changing hands under the typical 356,814

Recent Performance Chart

Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics Inc has with a one year low of $9.58 and a one year high of $30.41 and has a market capitalization of $0.

A total of 12 brokerages have released a report on Esperion Therapeutics Inc. Three brokerages rating the company a strong buy, eight brokerages rating the company a buy, two brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $32.67.

General Company Details For Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *